Ling-shan Zhou1, Ling-jie Xu1, Xue-qing Wang1, Yi-huan Huang1, Qian Xiao2. 1. Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. 2. Department of Geriatrics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. xiaoqian1956@126.com.
Abstract
BACKGROUND: Sarcopenia has been accepted as a new geriatric syndrome, which will become a common and important public health challenge. And angiotensin-converting enzyme inhibitors (ACEIs) have been shown to improve exercise capacity in elderly without heart failure. OBJECTIVES: To evaluate the effect of angiotensin-converting enzyme inhibitors (ACEIs) on physical function in elderly. DATA SOURCES: The Cochrane Library, PubMed, EMBASE and Web of Science were searched. ELIGIBILITY CRITERIA: All researches included were randomized controlled trials (RCTs) which compared any kind of ACEIs with placebo or other anti-hypertensives in elderly, and provided empirical data of grip strength and 6-min walk distance change from baseline. STUDY APPRAISAL AND SYNTHESIS METHODS: Risk of bias was systematically assessed by using the Cochrane risk of bias tool. Data of grip strength and 6-min walk distance change from baseline were collected and mean differences (MDs) were calculated along with 95% CI (confidence interval) by using a random effects model. RESULTS: In 3 RCTs including 337 elderly participants, ACEIs (n = 178) did not significantly improved 6-min walk distance (13.45, 95% CI: -16.71 to 43.61; P = 0.38) versus placebo or other antihypertensives (n = 159). In 3 RCTs including 499 elderly participants, grip strength was not significantly different (-0.67, 95% CI: -1.53 to 0.19; P = 0.12) between ACEIs (n = 260) and placebo or other antihypertensives (n = 239). LIMITATIONS: There exists only 4 RCTs and the number of participants is limited. Pooling of data were from different trials including different participant characteristics. And intervention is not strictly consistent. CONCLUSION: This study shows that ACEIs can not significantly improve walk distance or the age-related decline of muscle strength for older participants in clinical trials.
BACKGROUND:Sarcopenia has been accepted as a new geriatric syndrome, which will become a common and important public health challenge. And angiotensin-converting enzyme inhibitors (ACEIs) have been shown to improve exercise capacity in elderly without heart failure. OBJECTIVES: To evaluate the effect of angiotensin-converting enzyme inhibitors (ACEIs) on physical function in elderly. DATA SOURCES: The Cochrane Library, PubMed, EMBASE and Web of Science were searched. ELIGIBILITY CRITERIA: All researches included were randomized controlled trials (RCTs) which compared any kind of ACEIs with placebo or other anti-hypertensives in elderly, and provided empirical data of grip strength and 6-min walk distance change from baseline. STUDY APPRAISAL AND SYNTHESIS METHODS: Risk of bias was systematically assessed by using the Cochrane risk of bias tool. Data of grip strength and 6-min walk distance change from baseline were collected and mean differences (MDs) were calculated along with 95% CI (confidence interval) by using a random effects model. RESULTS: In 3 RCTs including 337 elderly participants, ACEIs (n = 178) did not significantly improved 6-min walk distance (13.45, 95% CI: -16.71 to 43.61; P = 0.38) versus placebo or other antihypertensives (n = 159). In 3 RCTs including 499 elderly participants, grip strength was not significantly different (-0.67, 95% CI: -1.53 to 0.19; P = 0.12) between ACEIs (n = 260) and placebo or other antihypertensives (n = 239). LIMITATIONS: There exists only 4 RCTs and the number of participants is limited. Pooling of data were from different trials including different participant characteristics. And intervention is not strictly consistent. CONCLUSION: This study shows that ACEIs can not significantly improve walk distance or the age-related decline of muscle strength for older participants in clinical trials.
Authors: A G Williams; M P Rayson; M Jubb; M World; D R Woods; M Hayward; J Martin; S E Humphries; H E Montgomery Journal: Nature Date: 2000-02-10 Impact factor: 49.962
Authors: Alfonso J Cruz-Jentoft; Francesco Landi; Eva Topinková; Jean-Pierre Michel Journal: Curr Opin Clin Nutr Metab Care Date: 2010-01 Impact factor: 4.294
Authors: Emanuele Marzetti; Riccardo Calvani; Jameson DuPree; Hazel A Lees; Silvia Giovannini; Dong-oh Seo; Thomas W Buford; Kindal Sweet; Drake Morgan; Kevin Y E Strehler; Debra Diz; Stephen E Borst; Natasha Moningka; Karina Krotova; Christy S Carter Journal: Age (Dordr) Date: 2012-05-26
Authors: G Abellan van Kan; Y Rolland; S Andrieu; J Bauer; O Beauchet; M Bonnefoy; M Cesari; L M Donini; S Gillette Guyonnet; M Inzitari; F Nourhashemi; G Onder; P Ritz; A Salva; M Visser; B Vellas Journal: J Nutr Health Aging Date: 2009-12 Impact factor: 4.075
Authors: Shelly L Gray; Aaron K Aragaki; Michael J LaMonte; Barbara B Cochrane; Charles Kooperberg; Jennifer G Robinson; Nancy F Woods; Andrea Z LaCroix Journal: J Am Geriatr Soc Date: 2012-11-23 Impact factor: 5.562
Authors: Deepa Sumukadas; Margaret Band; Suzanne Miller; Vera Cvoro; Miles Witham; Allan Struthers; Alex McConnachie; Suzanne M Lloyd; Marion McMurdo Journal: J Gerontol A Biol Sci Med Sci Date: 2013-11-07 Impact factor: 6.053
Authors: Margaret M Band; Deepa Sumukadas; Allan D Struthers; Alison Avenell; Peter T Donnan; Paul R Kemp; Karen T Smith; Cheryl L Hume; Adrian Hapca; Miles D Witham Journal: Trials Date: 2018-01-04 Impact factor: 2.279